Monitoring anticoagulant therapy with new oral agents

doi:10.5662/wjm.v5.i4.212

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7437)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

741

WORD

269

HTML

3999

Tables (1-2)

266

Sum=5275

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

896

Download

1266

Sum=2162

Dec 26, 2015 (publication date) through Jan 2, 2025

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Methodol. Dec 26, 2015; 5(4): 212-215
Published online Dec 26, 2015. doi: 10.5662/wjm.v5.i4.212

Table 1 Pharmacokinetic features of new oral anticoagulants[11,12]

	Apixaban	Rivaroxaban	Dabigatran
Posology	Twice daily	Once daily	Twice daily
Oral bioavailability	45%	> 80%	6%
Half life	12 h	7-11 h	12-17 h
Excretion	25% renal	66% renal (active and inactive)	80% renal

Citation: Ramos-Esquivel A. Monitoring anticoagulant therapy with new oral agents. World J Methodol 2015; 5(4): 212-215
URL: https://www.wjgnet.com/2222-0682/full/v5/i4/212.htm
DOI: https://dx.doi.org/10.5662/wjm.v5.i4.212